GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » TearLab Corp (OTCPK:TEAR) » Definitions » EV-to-EBIT

TearLab (TearLab) EV-to-EBIT : 9.93 (As of Apr. 26, 2024)


View and export this data going back to 2004. Start your Free Trial

What is TearLab EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, TearLab's Enterprise Value is $1.36 Mil. TearLab's EBIT for the trailing twelve months (TTM) ended in Mar. 2020 was $0.14 Mil. Therefore, TearLab's EV-to-EBIT for today is 9.93.

The historical rank and industry rank for TearLab's EV-to-EBIT or its related term are showing as below:

TEAR's EV-to-EBIT is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 20.23
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. TearLab's Enterprise Value for the quarter that ended in Mar. 2020 was $31.66 Mil. TearLab's EBIT for the trailing twelve months (TTM) ended in Mar. 2020 was $0.14 Mil. TearLab's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2020 was 0.43%.


TearLab EV-to-EBIT Historical Data

The historical data trend for TearLab's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TearLab EV-to-EBIT Chart

TearLab Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.86 -2.43 -2.04 10.01 107.89

TearLab Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.77 13.66 40.67 107.89 231.09

Competitive Comparison of TearLab's EV-to-EBIT

For the Diagnostics & Research subindustry, TearLab's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TearLab's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, TearLab's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where TearLab's EV-to-EBIT falls into.



TearLab EV-to-EBIT Calculation

TearLab's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1.360/0.137
=9.93

TearLab's current Enterprise Value is $1.36 Mil.
TearLab's EBIT for the trailing twelve months (TTM) ended in Mar. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TearLab  (OTCPK:TEAR) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

TearLab's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2020 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2020 ) =EBIT / Enterprise Value (Q: Mar. 2020 )
=0.137/31.658818
=0.43 %

TearLab's Enterprise Value for the quarter that ended in Mar. 2020 was $31.66 Mil.
TearLab's EBIT for the trailing twelve months (TTM) ended in Mar. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TearLab EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of TearLab's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


TearLab (TearLab) Business Description

Traded in Other Exchanges
N/A
Address
150 LaTerraza Boulevard, Suite 101, Escondido, CA, USA, 92025
TearLab Corp is a part of the diagnostic industry. It is an in-vitro diagnostic company based in the United States. TearLab has commercialized a proprietary tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for highly sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The company operates through its wholly-owned subsidiary, TearLab Research Inc. Most of the company's revenue is derived from the United States region.
Executives
Anthony E Altig director C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, JERSEY CITY NJ 07302
Cr Group L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Adrienne L Graves director 125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Gilbert S Omenn director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
John Y Caloz officer: Chief Financial Officer ETON AVE, C/O INTERNATIONAL REMOTE IMAGING SYS, CHATSWORTH CA 91311